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Abstract
Background: Hypoxia-inducible expression of the erythropoietin (EPO) gene is mediated principally by hypoxia-inducible
factor 2a (HIF-2a) in Hep3B cells under physiologic conditions. How/whether p300/CBP and the members of p160
coactivator family potentiate hypoxic induction of endogenous EPO and other HIF-2a and hypoxia-inducible factor 1a (HIF-
1a) target genes remains unclear.
Methodology/Principal Findings: We demonstrate, using chromatin immunoprecipitation (ChIP) analysis, that the histone
acetyl transferase (HAT) coactivators p300, SRC-1 and SRC-3 are recruited to the 39 enhancer of the EPO gene upon hypoxic
stimulation, and that each associates with the enhancer in a periodic fashion. Hypoxia induced acetylation of the EPO gene
59 promoter at histone 4 and lysine 23 of histone 3. Knocking down SRC-3, but not SRC-1 or SRC-2, using short interfering
RNAs (siRNAs), reduced EPO transcriptional activity. Knocking down p300 resulted in dramatic down-regulation of hypoxic
stimulation of EPO gene transcription, negated recruitment of RNA polymerase II to the gene’s promoter, and eliminated
hypoxia-stimulated acetylation at the promoter and recruitments of SRC-1 and SRC-3 to the enhancer. The inhibitory effects
of knocking down p300 and the chromatin remodeling coactivator, Brm/Brg-1, on EPO transcription were additive,
suggesting that p300 and Brm/Brg-1 act independently. p300 was also required for hypoxia induced transcription of the
HIF-1a target gene, VEGF, but was dispensable for induction of two other HIF-1a target genes, PGK and LDHA. Knocking
down CBP, a homolog of p300, augmented hypoxic induction of VEGF, LDHA and PGK. Different HIF target genes also
exhibited different requirements for members of the p160 coactivator family.
Conclusions/Significance: p300 plays a central coactivator role in hypoxic induction of EPO. The coactivators exhibit
different specificities for different HIF target genes and each can behave differently in transcriptional regulation of different
target genes mediated by the same transcription factor.
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Introduction
Tissue oxygen concentration is an important regulatory stimulus
for many physiological and pathological processes [1,2]. Adaptation
to hypoxia depends in part on appropriate alterations in the
expression of a number of physiologically relevant genes. Induction
of the erythropoietin (EPO) gene by hypoxia is central to the
regulation of the oxygen-carrying capacity of the blood [3]. Cellular
adaptation to hypoxia is mediated in large part by the transcrip-
tional activation of genes by Hypoxia-inducible Factor (HIF). HIFs
are heterodimeric proteins containing one a subunit and one b
subunit. HIF-1a and HIF-2a (collectively called the HIF-a subunits)
are both expressed widely, as is HIF-1b (also called the Aryl
Hydrocarbon Receptor Nuclear Translocator {ARNT}), while
HIF-2b has a more limited tissue distribution. Under normoxic
conditions, the HIF-a subunits are hydroxylated on key proline
residues located in the C-terminal half of the proteins by O2–
dependent prolyl hydroxylases, which allows for their recognition by
the von Hippel-Lindau (pVHL) tumor suppressor protein that
targets HIF-a for proteosomal degradation. Another level of HIF-
1a inhibition occurs through the hydroxylation of an asparagine
residue, also located towards the C-terminus of the protein, by the
O2 -dependent Factor Inhibiting Hypoxia Inducible Factor-1a
(FIH). This hydroxylation prevents HIF-1a from interacting with
the coactivator p300 under normoxic conditions [4]. During
hypoxia, HIF-1a dimerizes with its partner ARNT, and this
complex then binds hypoxia response elements (HREs) in the
promoter regions of target genes and up-regulates their transcrip-
tion. Expression profiling and functional studies have revealed that
the HIF-a subunits regulate both shared and unique target genes.
Domain-swapping and chromatin immunoprecipitation studies
have shown that selective HIF target gene activation is not based
on the DNA-binding properties of these factors, since both HIF-a
subunits can bind to the endogenous HREs of hypoxia-responsive
genes, but that selectivity resides in their C-terminal regions,
harboring their transcriptional activation domains.
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The human EPO gene has been a powerful tool for studying the
regulation of gene expression by HIF, since that the hypoxic
induction of EPO expression is the most robust among hypoxia-
inducible genes, and because the enhancer and promoter are
located in 39 and 59 flanking regions of the gene, respectively, and
widely separated (approximately 3 kb) from each other. Tran-
scriptional regulation of the EPO gene is achieved by the
concerted action of several transacting factors interacting with
the proximal promoter region and with the 39 untranslated
enhancer region of the gene [5–11].
In eukaryotes, the regulation of transcription initiation requires
that transcription factors function in the context of chromatin.
Several classes of chromatin remodeling enzymes have been
identified that facilitate transcription from the chromatin template,
including histone acetyltransferases (HATs) and ATP-dependent
remodeling enzymes [12]. p300 and its homolog, the CREB-
binding protein (CBP), possess intrinsic HAT activity. These
coactivators bind a number of sequence-specific transcriptional
activators and have been suggested to be central integrators of
transcriptional signals from various signals transduction pathways
[13]. They have been implicated in HIF-mediated transcriptional
activation of hypoxia-inducible genes via direct interactions with
HIF-1a [14,15,16,17]. The p160 steroid receptor coactivator
(SRC) gene family contains three homologous members, SRC-1
(NCoA-1), SRC-2 (GRIP1, TIF2, or NCoA-2) and SRC-3 (p/CIP,
RAC3, ACTR, AIB1, or TRAM-1), which serve as transcriptional
coactivators for nuclear receptors and certain other transcription
factors [18]. They possess many features in common and may be
able to partially compensate for each other’s functions [19,20,21].
SRC-1 and SRC–3 also possesses intrinsic HAT activity, though
the HAT activities of SRC-1 and SRC–3 are much weaker than
those of p300 and CBP [22,23]. SRC-1 and SRC–2 have been
shown to be able to interact with HIF-1a and to enhance its
transactivation potential in a hypoxia-dependent manner, and this
interaction is mediated by CBP [14,15]. However, these findings
are based on protein-protein binding, co-localization and reporter
assays. It remains unclear how these coactivators contribute to the
transcription of endogenous hypoxic-inducible genes and to
histone modification at the promoters of these genes.
In this study, we investigated the roles of p300 and p160 family
members in transcriptional regulation of the EPO gene and in
chromatin modification at the native promoter region of the gene.
We also investigated the relationship among p300, the p160 family
members and the Brm/Brg-1 ATPase subunits of the mammalian
SWI/SNF chromatin-remodeling complex in transcriptional
regulation of the EPO gene and other HIF target genes.
Methods
Cell Culture and antibodies
The Hep3B cell line was purchased from ATCC and grown in
modified Eagle medium (ATCC) with 10% fetal calf serum
(Omega), L-glutamine (Invitrogen), fungizone, and penicillin-
streptomycin (Invitrogen) at 37uC and 5% CO2. The Brm (N-
19), Brg-1 (H-88), p300 (N-15), SRC-1 (M-341), and SRC-3 (C-20)
antibodies were purchased from Santa Cruz Biotechnology, and
the SRC-2 antibody from BD Biosciences were used for the both
ChIP and western Blot assays, except that the SRC-1 (128E7)
antibody from Cell Signaling, and the SRC-3 (1A8) antibody from
Santa Cruz were used for western blot analysis. The Antibodies to
Ac-K5, K8, K12, K18-H4, Ac-K14-H3, and Ac-K23-H3 were
purchased from Upstate Biotechnology. The affinity-purified
rabbit polyclonal antibody to ARNT was described previously
[24].
RNA interference in Hep3B cells
The pQCXIPgfp vector (a kind gift from Dr. Stephen Smale,
UCLA), was modified for retroviral delivery of RNAi. The mouse U6
promoter was cloned into the NheI site within the 39LTR [25].
Oligonucleotides encoding siRNA hairpins against p300 and SRC-2
were then annealed and cloned downstream of the U6 promoter. The
targeting sequences for p300 and SRC-2 were 59-
CCCCTCCTCTTCAGCACCA-39 and 59-AGAGCAAACT-
CATCCGTTC-39, respectively. For retrovirus generation, 293T
cells were purchase from ATCC and grown in DMEM with 10%
FBS and penicillin/streptomycin. Cells were grown to 90%
confluency in 10-cm dishes and transfected with the retroviral
vectors and the 10A1 packaging vector using Lipofectamine 2000
(Invitrogen). The medium was replaced 24 h post-transfection. The
virus supernatants were collected 36 and 48 h after transfection,
filtered through a 0.45-mm syringe filter, and stored at 280uC. For
retroviral infection, Hep3B cells (36105/well) were seeded in six-well
plates, and 2 mL of virus supernatant supplemented with polybrene
(8 mg/mL final concentration) was added to the cells. Spin infections
were performed at 2500 rpm for 1.5 h at 30uC. One day after the
second infection, puromycin (3 mg/mL) selection was started and
GFP expression was monitored by flow cytometry. RNA oligonucle-
otides were used for simultaneous RNAi knockdown of both Brm and
Brg-1 (siB/B) [26], and for SRC-1 and SRC-3. The siRNA
oligonucleotides were synthesized by Qiagen and annealed according
to the manufacturer’s protocol. The sense sequences of siSRC-1,
siSRC-3, siB/B, siCBP and SCX, a scrambled RNA oligonucleotide,
are r(CUCCUAAUAUUUCGACAUUAA)d(TT), r(CAG-
GAUUAUAUGGACAGACAU)d(TT), r(GCUGGAGAAGCAG-
CAGAAG)d(TT), r(GCACAGCCGTTTACCAUGAUU) and
r(UUCUCCGAACGUGUCACGU)d(TT). Hep3B cells cultured
in 6-well plates were transfected at 30% cell confluency using the
Oligofectamine transfection reagent (Invitrogen). Western blot was
performed to monitor degree of knockdown of the corresponding
proteins.
Reverse Transcription and Real-time PCR
Cells transfected with siRNAs were harvested forty-eight hours
after transfection. Cells stably expressing the short hairpin RNAs
were harvested after selection with puromycin. For measuring the
mRNA of EPO, the plates were exposed to hypoxia 48 h after
transfection and cultured for a further 24 h. Total RNA was
prepared from transfected or infected cells using the RNeasy
Micro kit (Qiagen). 1.5 mg of total RNA was reverse-transcribed
using a Super script III Reverse Transcriptase kit (Invitrogen). The
RT Real-Time SYBR/ROX PCR Master Mix was purchased
from SuperArray; and PCR analysis was performed on an Applied
Biosystems 7500 Real-Time PCR System, according to the
instructions of the manufacturer. The primer sets for RT-PCR
for the ribosomal 36B4, EPO and VEGF gene were as previously
described (26). The primer sets for RT-PCR for LDHA and PGK
are 59-AAGTGGTTGCAATCTGGATTCAG-39 and 59-
GGTGAACTCCCAGCCTTTCC-39; 59-CGCTTTCATGTG-
GAGGAAGAA-39 and 59- TGGCTCGGCTTTAACCTTGT-
39, respectively. The mRNA levels were normalized to that of the
36B4. Each of the real-time PCRs was done three times and one
representative result is presented in each case. The result is an
average from three real-time PCR reactions with the same
template.
Chromatin Immunoprecipitation Assay
The procedure was performed using a kit purchased from Upstate
Biotechnology, according to the protocol recommended by the
manufacturer. Briefly, Hep3B cells were treated with hypoxia or
Coactivators and HIF
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100 mM desferrioxamine (DFO), for the indicated times. Cross-
linking was achieved by adding formaldehyde to a final concentration
of 1% at 37uC for 10 min. Cells were washed twice with ice-cold
phosphate-buffered saline and collected in 1 ml of ice-cold
phosphate-buffered saline. Cells were pelleted at 7006g at 4uC and
resuspended in 0.3 ml of cell lysis buffer (50 mM Tris-HCl (pH 8.1),
10 mM EDTA, 1% SDS, Roche Complete protease inhibitor
mixture), and incubated on ice for 10 min. Cell lysates were sonicated
to give a DNA size range from 200 to 900 bp. Samples were
centrifuged for 10 min at 4uC. Supernatants were diluted 10-fold
with dilution buffer (16.7 mM Tris-HCl, pH 8.1, 1.1% Triton X-
100, 1.2 mM EDTA, 167 mM NaCl, 0.01% SDS, and Complete
protease inhibitor mixture). The solutions were pre-cleared with 80 ml
of salmon sperm DNA/protein A agarose slurry for 30 min at 4uC,
and then treated with antibodies overnight at 4uC. Immune
complexes were collected using 60 ml of a salmon sperm DNA/
protein A agarose slurry or protein G agarose (Amersham Pharmacia
Biotec). The beads were pelleted and washed sequentially in the
following buffers: low salt wash buffer (20 mM Tris-HCl (pH 8.1),
150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton X-100); high
salt wash buffer (20 mM Tris-HCl (pH 8.1), 500 mM NaCl, 2 mM
EDTA, 0.1% SDS, 1% Triton X-100), LiCl wash buffer (10 mM
Tris-HCl (pH 8.1), 0.25 M LiCl, 1% Nonidet P-40, 1% deoxycho-
late, 1 mM EDTA), and TE buffer (twice). Immuno-complexes were
extracted from the beads with 1% SDS-0.1 M NaHCO3. Cross-
linking was reversed by heating the eluates at 65uC overnight. The
eluates were then digested with proteinase K at 45uC for 1 h. DNA
was purified using a DNA purification kit (Qiagen). The 39 enhancer
region (+39 to +295 from the 39 end of exon 5), and the 59 promoter
region (2368 to +18 from the transcription start site) of the EPO gene
were amplified by PCR. The primer sequences for the enhancer and
promoter of the EPO gene were 59-GCCCTACGTGCTGTCT-
CACAC-39 and 59-CCTTGATGACAATCTCAGCGC -39; 59-
ATGACCCACACGCACGTCTGCAGCAG-39 and 59-CGGGG-
CTGTTATCTGCATGTGTGCGT-39, respectively. For real-time
PCR analysis, the primer sequences for the enhancer and promoter
were 59- GCCCTACGTGCTGTCTCACAC -39 and 59-ATT-
GACCAGCGTAGGCAGAGC -39; 59-TGGCGACCCCTCACG-
CACACAGCC -39 and 59-TGGCCCAGGGACTCTGCGG-
CTCTGG -39, respectively. Teal time PCR was performed as
described in quantifying mRNA level. The DNA levels were
normalized to those of the appropriate chromatin inputs after they
are subtracted with DNA signals given by ChIP using normal rabbit
or goat IgG. Each real-time PCR analysis was performed three times
on the same ChIP and a representative result is presented. The result
is an average from three real-time PCR reactions with the same
template, unless specifically noted. Student’s t test was used to
determine the significances of differences between samples.
Results
Coactivator requirements during hypoxic induction of
EPO transcription
p300 has been shown to be required for the hypoxic induction
of a reporter gene driven by the enhancer of the EPO gene, to
associate with HIF-1a in vitro, and to form a complex with the
HRE and HIF-1a under hypoxic conditions in a gel shift assay
[16]. Furthermore, using transient transfected EPO enhancer
driven reporter gene assays, immunoprecipitation assays and
colocalization assays, two research groups found that SRC-1,
SRC-2 and CBP, a homolog of p300, bind to HIF-1a and
potentiate its transcriptional activity [14,15]. We thought it
important to extend these studies by investigating the roles of
these coactivators in hypoxia induction of the endogenous EPO
gene in its normal chromosomal configuration. Moreover, it
should be noted that the hypoxic induction of EPO is mainly
mediated by HIF-2a, rather than HIF-1a, in Hep3B cells under
physiological conditions, although these cells express both HIF-a
forms [27,28]. The expression of EPO has also been shown to be
dominantly regulated by HIF-2a in the adult mouse [28]. In order
to examine the roles played by coactivators in hypoxia-induced
transcription of the EPO gene, we knocked down individual
coactivators using RNA interference. p300, SRC-1, SRC-2 and
SRC-3 were knocked down in Hep3B cells by short hair-pin
siRNA or siRNA oligonucleotides (Fig. 1A). While depletion of
p300 and SRC-3 resulted in a significant reduction in transcription
of the endogenous EPO gene triggered by hypoxia, depletion of
neither SRC-1 nor SRC-2 inhibited the induced expression of the
gene, suggesting either a redundancy of these p160 coactivators, or
a dispensable role for both SRC-1 and SRC-2 in the transcription
of the gene (Fig. 1B). We further found that desferrioxamine
(DFO), a hypoxia mimicking reagent, stimulated a persistent
association of RNA polymerase II (pol II) with the promoter in
Hep3B/shSCX cells, which express a scrambled sequence with a
short hairpin structure, but not in Hep3B/shp300 cells expressing
a short hairpin RNA targeting p300, suggesting that p300 is
required for the hypoxia induced association of pol II with the
promoter (Fig. 1C). To exclude the possibility that the inhibitory
effects of sip300 and siSRC-3 on EPO result from off target effects,
we confirmed these results using siRNAs with different target
sequences (Fig. S1 of Supplementary Information). We also
thought it is important to confirm the lack of effect of depleting
SRC-1 on the transcription of the EPO gene using another siRNA
with a different inhibitory squence (Fig. S1 of Supplementary
Information), since SRC-1 has been reported to play a role in the
transcription of HIF-1a target genes in several independent studies
using reporter gene assays.
Coactivator Recruitment to the 39 Enhancer Region of
the EPO gene in Response to Hypoxic Stimulation
We then performed ChIP analysis to test whether the
coactivators are recruited to the 39 enhancer region of the gene
after hypoxia treatment. Antibodies against Arnt (HIF-1b), a
common binding partner for both HIF-1a and HIF-2a, p300,
SRC-1, and SRC-3 efficiently precipitated the 39 enhancer region
of the EPO gene in a hypoxia-dependent fashion (Fig. 2A),
indicating that each associates with this region in response to
hypoxic induction. p300 appeared to dissociate from the enhancer
at the 5-hour time point, implying that it may bind to the enhancer
in a cyclical fashion. Different coactivator complexes are recruited
with distinct kinetics to target promoters by the corresponding
transcription activators, as is evident from a number of well
studied nuclear receptor systems [29,30,31]. Little is known about
the kinetics of coactivator recruitment to the promoters or
enhancers of hypoxia-inducible genes mediated by HIF. We
therefore carried out kinetic ChIP studies on the 39 enhancer
region of EPO using an antibody against p300 in Hep3B cells. It
was not feasible to use hypoxia for these experiments because the
oxygen concentration fluctuates each time the incubator is opened,
and it also takes a relatively long time for oxygen to equilibrate in
the culture medium. We therefore used DFO. As shown in Fig. 2B,
after quantifing the DNA obtained from ChIP for p300 using real
time PCR, we found that p300 bound to the enhancer as quickly
as 25 min after the addition of DFO, and associated with the
enhancer in a periodic fashion. To confirm that this periodicity is
not particular to DFO, we investigated the kinetics of p300
binding to the enhancer in cells cultured under hypoxia, using a
time course with prolonged intervals between each time point.
Coactivators and HIF
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Again, we observed that p300 bound to the enhancer in a periodic
fashion, while Arnt bound to the DNA stably and persistently
(Fig. 2C), indicating that the periodic fashion of p300 recruitment
does not result from a periodic association of the HIF-2a/Arnt
transcription factor with the enhancer of the gene. We failed to
detect any hypoxia induced binding of SRC-2 to the enhancer
(data not shown), which is consistent with our finding that a siRNA
to SRC-2 did not inhibit hypoxia induction of EPO.
p300 is required for the recruitment of SRC-1 and SRC-3
to the enhancer of the EPO gene
In gene regulation mediated by nuclear hormone receptors, the
p160 coactivators play major roles in chromatin remodeling and
the assembly of general transcription factors through direct and
indirect recruitments of other coactivators, including CBP/p300,
although additional direct interactions between CBP/p300 and
nuclear hormone receptors have also been observed [32,18]. The
Figure 1. Requirements for coactivators in induction of the EPO
gene by hypoxia. A. whole cell extracts were prepared from Hep3B/
shscx, Hep3B/shp300, Hep3B/shSRC-2 and Hep3B cells transfected with
siSRC-1 and siSRC-3 RNA duplexes for 72 h and then subjected to
western blot analysis using the indicated antibodies. B, for analysis of
EPO mRNA expression, the cells were treated with 1% O2 for 24 h,
(Hep3B cells were transfected with siSRC-1 and siSRC-3 and 48 h later
were treated with 1% O2 for additional 24 h). Total RNA was then
isolated and subjected to reverse transcription and real-time PCR. EPO
mRNA levels were normalized to the levels of the constitutively
expressed 36B4 gene, encoding a ribosomal subunit. ** Indicates
statistically significant difference (p,0.01). C, Hep3B/shscx and Hep3B/
shp300 cells were treated with 100 mM DFO, harvested at the indicated
time points, and subjected to ChIP analysis using an antibody directed
to pol II. The precipitated chromatin was quantified by real time PCR
using a pair of primers flanking the promoter of the EPO gene.
doi:10.1371/journal.pone.0010002.g001
Figure 2. Coactivators are recruited to the EPO promoter upon
hypoxic induction. A, Hep3B cells cultured under 21% O2 or 1% O2
for 3 h and 5 h were cross-linked and subjected to sonication and
immunoprecipitation with the indicated antibodies. The precipitated
chromatin was amplified by PCR using the primers flanking the
enhancer of the EPO gene. B, Hep3B cells were treated with 100 mM
DFO, harvested at the indicated time points, and subjected to ChIP
analysis using an antibody directed to p300. The precipitated chromatin
was quantified by real time PCR using a pair of primers flanking the
enhancer of the EPO gene. C, ChIP was performed as described in A,
except that the cells were harvested at different time points and only
antibodies for Arnt and p300 were used.
doi:10.1371/journal.pone.0010002.g002
Coactivators and HIF
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p160 coactivators and CBP/p300 are also able to enhance the
transactivition potential of HIF-1a in transient reporter gene
assays, but in contrast to the above situation with the nuclear
hormone receptor, CBP is required for SRC-1 to interact with
HIF-1a, suggesting a major role for CBP in HIF-1amediated gene
regulation [14,15]. We therefore examined the relationship of
p300 to other coactivators during hypoxic induction of the EPO
gene. We first investigated whether p300 impacts the recruitment
of other coactivators to the enhancer of EPO. SRC-1 and SRC-3
bound to the 39 enhancer region of EPO as quickly as 25 min after
the addition of the hypoxia mimetic DFO to Hep3B/shscx cells,
and each bound to the enhancer in a cyclic fashion. When we
performed the same analysis in Hep3B/shp300 cells treated with
DFO, we could not detect recruitment of either SRC-1 or SRC-3
to the enhancer of the gene throughout the whole time course,
demonstrating that the recruitment of both SRC-1 and SRC-3 are
dependent on p300 (Fig. 3A). Similarly, the hypoxia-stimulated
recruitment of both SRC-1 and SRC-3 to the EPO enhancer was
eliminated in cells knocked down for p300 (Fig. 3B). In contrast,
recruitment of Arnt to the enhancer was unimpeded in Hep3B/
shp300 cells either cultured under hypoxia or treated with DFO
(Fig. 3C).
Relationship between p300 and Brm/Brg-1
We previously showed that Brm and Brg-1 are recruited to the
enhancer of the EPO gene and that their diminution reduces
induction of the EPO gene by hypoxia [26]. In this study, we
investigated whether p300 affects hypoxia- stimulated recruitment
of Brm/Brg-1 to the enhancer. As shown in Fig. 4A, knocking
down p300 did not significantly impair the hypoxia-induced
recruitment of either Brm or Brg-1 to the enhancer, suggesting
that p300 and Brm/Brg-1 belong to different protein complexes.
Hypoxic induction of EPO in cells with triple knock down of p300,
Brm and Brg-1 was lower than that in cells with only p300
knocked down or in cells with only Brm/Brg-1 knocked down
(Fig. 4B), further suggesting that p300 and Brm/Brg-1 belong to
different protein complexes. Using ChIP analysis, we also found
that simultaneously knocking down Brm and Brg-1 inhibited the
hypoxia-stimulated recruitment of RNA polymerase II (pol II) to
the EPO promoter, indicating that the SWI/SNF chromatin
remodeling complex is required for the hypoxia induced
association of pol II with the promoter (Fig. 4C).
P300 is required for acetylation of histone at the EPO
promoter associated with transcriptional induction of the
EPO gene
Given that coactivators with intrinsic HAT activity, p300, SRC-
1 and SRC-3, were recruited to the enhancer of the EPO gene in
response to hypoxic stimulation, we speculated that, via a DNA-
looping mechanism, the HIF/coactivator complexes modify
histones at the 59 promoter region, so as to make it become
permissive for the assembly of an active preinitiation complex. We
therefore analyzed histone modifications at the promoter region in
Hep3B/shscx cells, focusing on lysine residues shown to be
acetylated by p300, SRC-1 and SRC-3 in in vitro acetylation
assays. Since the recruitments of SRC-1 and SRC-3 to the
enhancer of the EPO gene were eliminated in cells in which p300
is knocked down, we also hypothesized that hypoxic induction of
histone acetylation at the promoter of the gene would be reduced
in cells with p300 knocked down if p300, SRC-1 and/or SRC-3
are responsible for these acetylations. Therefore, we performed the
same analysis in Hep3B/shp300 cells. Since hypoxia (1% O2)
treatment resulted in a greater induction of the EPO gene than
Figure 3. Hypoxia induced recruitments of the p160 coactiva-
tors are dependent on p300. A, Hep3B/shscx and Hep3B/shp300
cells were treated with 100 mM DFO, harvested at the indicated time
points, and subjected to ChIP analysis using antibodies directed to SRC-
1 or SRC-3. The precipitated chromatin was quantified by real time PCR.
B, Hep3B/shscx and Hep3B/shp300 cells were treated with 1% O2 for
3 h and then subjected to ChIP analysis using antibodies against SRC-1
or SRC-3. The DNA obtained was quantified using real time PCR. C,
Hep3B/shscx and Hep3B/shp300 cells were treated with 100 mM DFO
for 1 h or 1% O2 for 3 h and then subjected to ChIP analysis using an
antibody against Arnt. The precipitated chromatin was quantified by
real time PCR.
doi:10.1371/journal.pone.0010002.g003
Coactivators and HIF
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DFO, we treated the cells with 1% O2 for these experiments,
except in the case for acetylation at H4 K5, K8, K12 and/or K16,
since this acetylation could also be observed at the promoter
region of the EPO gene in cells treated with DFO. Since the
antibody used in this last experiment was produced with a peptide
corresponding to amino acids 2–19 of Tetrahymena histone H4
(AGG(Ac)KGG(Ac)KGMG(Ac)KVGA(Ac)KRHS-C), acetylated
on lysines 5,8,12 and 16, as antigen, we cannot tell which specific
lysine(s) is acetylated. We found that lysines at positions 23 of
histone 3 (H3K23), previously shown to represent a potential in vivo
acetylation substrate of CBP/p300 in the pS2 promoter [33,34],
was strongly acetylated after hypoxic stimulation, that this
acetylation was persistent throughout the time course of hypoxia
induction, and that the acetylation were eliminated in Hep3B/
shp300 cells (Fig. 5A). We confirmed this conclusion by real time
PCR quantization of the ChIP data at one time point (Fig. 5B). We
also observed that hypoxia induced strong acetylation at lysines 5,
8, 12, and/or 16 of histone 4, which represent acetylation
substrates of both p300 and SRC-1 [35,22], in Hep3B/shscx cells
but not in Hep3B/shp300 cells (Fig. 5C). Furthermore, acetylation
at (one or more of) these sites was observed after DFO treatment in
Hep3B/shscx but not in Hep3B/shp300 cells, and occurred in a
periodic fashion (Fig. 5D). Thus p300 is required for hypoxia
stimulated acetylations at these sites. It is of interest that the
kinetics of acetylations of H4K5K8K12K16 at the EPO promoter
is similar to the kinetics of the recruitment of p300 to the EPO
enhancer, implying that H4K5K8K12 and/or K16 might be
direct targets of acetylation by p300 in vivo. In contrast, although
knocking down Brm and Brg-1 impaired the hypoxia induced
association of pol II with the promoter (Fig. 4D), it did not inhibit
the acetylations at H4K5K8K12K16 (Fig. 5E), indicating that
Brm/Brg-1 is not required for histone modifications at the
promoter, as least for acetylation at H4K5K8K12K16.
The coactivators exhibit highly specificities towards HIF
target genes
CBP/p300 and the p160 coactivators are known to interact
with the transactivation domain of HIF-1a in vitro. However, their
roles in transactivation of endogenous target genes of HIF are
unclear. We therefore examined hypoxia induction of a number of
HIF target genes in Hep3B cells in which these coactivators were
knocked down individually. We found that p300 and SRC-3, but
not SRC-1, are required for the hypoxia induced expression of the
VEGF gene, a target gene of HIF-1a in Hep3B cells (Fig. 6A),
which is thus similar to EPO with regard to the requirement of
coactivitors for its transcription, although EPO is uniquely a HIF-
2a target in these cells. All these coactivators appeared to be
dispensible for hypoxia-induced transcription of the HIF-1a target
gene, LDHA, while SRC-3 appeared to be required for hypoxia
induced transcription of the HIF-1a target gene, PGK (Fig. 6B
and C). We confirmed these results using siRNAs with different
target sequences (Fig. S1 of Electronic Supplementary Informa-
tion). We previously showed that Brm and Brg-1 are required for
hypoxia induced transcription of the EPO gene but not for that of
the VEGF gene in Hep3B cells [26]. In the current study, we
found that Brg-1 and/or Brahma appear to be required for
hypoxia induced transcription of both the LDHA and PGK genes
(Fig. 6D and E). Finally, we investigated the role of the p300
homolog, CBP, in hypoxia induced transcription of the genes.
Knocking down CBP in Hep3B cells by siRNA (Fig. 7A)
significantly decreased the hypoxia induced transcription of the
EPO gene (although to a less extent than knocking down p300),
suggesting that both p300 and CBP are required for hypoxia
induction of EPO and that neither can completely compensate for
Figure 4. The relationship between p300 and Brm/Brg-1. A,
Hep3B/shscx and Hep3B/shp300 cells were treated with 1% O2 for 3 h
and subjected to ChIP analysis using antibodies against Brm or Brg-1.
The precipitated chromatin was quantified by real time PCR. B, Hep3B/
shscx and Hep3B/shp300 cells were transfected with siscx or siB/B. 48 h
after transfection, the cells were treated with 1% O2 for 24 h. Total RNA
were then isolated and subjected to reverse transcription and real-time
PCR. C, Hep3B cells were transfected with siscx or siB/B. 72 h after
transfection, the cells treated with 1% O2 for 3.5 h and then subjected
to ChIP analysis using an antibody for RNA polymerase II. The
precipitated chromatin was quantified by real time PCR. ** Indicates
statistically significant difference (p,0.01).
doi:10.1371/journal.pone.0010002.g004
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the function of the other (Fig. 7B). Surprisingly, knocking down
CBP enhanced the hypoxic induction of the VEGF, PGK and
LDHA genes in Hep3B cells (Fig. 7C, D and E), suggesting that
CBP and p300 are not functionally interchangeable in transactiva-
tion of the VEGF gene and that p300 and CBP are either
dispensable or redundant in the transcription of the LDHA and
PGK genes. The enhancement of these genes’ transcription upon
knocking down CBP, we speculate, results from the recruitment of
other coactivators even more potent than CBP. Of interest, we
observed a similar enhancement of EPO transcription by depletion
of endogenous Brg-1 in our previous study [26]. Taken together,
these data indicate that the roles of these coactivators in
transcription are highly gene-specific even for the transcription
of the genes mediated by the same transcriptional factor, either
HIF-1a or HIF-2a.
Discussion
In mammalian systems, the EPO gene is the most hypoxia-
responsive gene identified, being inducible by hypoxia up to 100-fold.
Transcriptional regulation is achieved by the concerted action of
several transacting factors interacting with the 59 proximal promoter
region and with the 39 untranslated region of the EPO gene, which
are widely separated from each other. Hypoxic regulation of HIF
Figure 5. p300 is required for hypoxia-stimulated histone modifications at the EPO promoter. A, Hep3B/shscx and Hep3B/shp300 cells
were cultured under 1% O2, harvested at the indicated time points, and subjected to ChIP analysis using an antibody directed to acetylated H3K23. B,
DNA obtained from the ChIP described in A was quantified by real time PCR using a pair of primers spanning the promoter of the EPO gene. C,
Hep3B/shscx and Hep3B/shp300 cells were cultured under 1% O2, harvested at 0 and 3.5 h, and subjected to ChIP analysis using antibodies directed
to acetylated H4K5K8K12K16. The precipitated chromatin was quantified by real time PCR. D, Hep3B/shscx and Hep3B/shp300 cells were treated with
100 mM DFO, harvested at the indicated time points, and subjected to ChIP analysis using an antibody directed to acetylated H4K5K8K12K16. The
precipitated chromatin was quantified by real time PCR. E, Hep3B cells were transfected with siscx or siB/B. 72 h after transfection, the cells treated
with 1% O2 for 3.5 h or untreated (0 h) and then subjected to ChIP analysis using an antibody for acetylated H4K5K8K12K16.
doi:10.1371/journal.pone.0010002.g005
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activity is partially mediated by the hydroxylation of an asparagine
residue in the C-terminus of HIF-1a and HIF-2a by the O2-
dependent FIH (factor inhibiting HIF). Hydroxylation of the
asparagine residue has been shown to prevent interaction of p300
with HIF-1a in vitro [4]. p300 has also been shown to be required for
the hypoxic induction of a reporter gene driven by the EPO
enhancer, to form a complex with the HRE and HIF-1a under
hypoxic conditions in a gel shift assay, and to be required for hypoxia
induction of endogenous VEGF [14,15,16]. However, information
about how p300 regulates endogenous HIF target genes is still very
limited. In particular, we addressed the following issues. (i) Are all or
only some of the members of the p160 family involved? (ii) How do
the coactivators cooperate with each other to regulate hypoxia
induction of the EPO gene? (iii) What covalent chromatin
modifications occur at the promoter region of the EPO gene in
response to hypoxia treatment? (iv) What are the roles of p300 and
the p160 family of coactivators in chromatin modification at the
promoter? (v) What are the roles of these coactivators in
transcriptional regulation of different endogenous HIF-1a and
HIF-2a target genes? (vi) Both CBP and its homolog, p300 have
been shown to bind to the C-terminal of HIF-1a and potentiate the
transcriptional activities of both HIF-1a and HIF-2a in transient
reporter assays. Little is known about potential differences between
CBP and p300 in potentiating the transcriptional activities of HIF-1a
and HIF-2a. Are they interchangeable in potentiating hypoxia
induced transcription of the EPO gene and other HIF target genes?
The results of our studies establish a central coactivator role for p300
in hypoxia induction of EPO.
Depletion of p300 or SRC-3 resulted in a significant reduction
in transcription of the endogenous EPO gene triggered by
Figure 6. Roles of coactivators in hypoxia induced transcription of HIF-1a target genes. A, B and C, the hypoxia induced transcription of VEGF,
PGK and LDHA genes were examined as described in Fig. 1B. D and E, Hep3B were transfected with siscx or siB/B. 72 h after transfection, the cells were
treated with 1% O2 for 24 h. Then total RNA were isolated and subjected to reverse transcription and real-time PCR for analysis of VEGF, LDHA and PGK
mRNA expression. N: normoxia. H: hypoxia. ** indicates statistically significant difference (p,0.01). * indicates statistically significant difference (p,0.05).
doi:10.1371/journal.pone.0010002.g006
Coactivators and HIF
PLoS ONE | www.plosone.org 8 April 2010 | Volume 5 | Issue 4 | e10002
hypoxia. To our surprise, depletion of neither SRC-1 nor SRC-2
affected the hypoxia induction of the EPO gene, although both
coactivators have been shown to potentiate the transcriptional
activity of HIF-1a in transient transfection assays. Thus, neither
SRC-1 nor SRC-2 appears to be required for hypoxic stimulation
of the EPO gene or alternatively, these p160 coactivators function
redundantly in transactivation of the gene. RNA polymerase II
(pol II) persistently associated with the promoter throughout the
time course of hypoxic treatment, and this association was
eliminated by knocking down p300, indicating that p300 is
important for the initiation of the transcription of the gene. p300,
SRC-1 and SRC-3 were recruited to the 39 enhancer region of the
EPO gene in response to hypoxic stimulation, bound to the
enhancer as soon as 25 minutes after treatment with the hypoxia
mimic, desferrioxamine, and subsequently associated with the
enhancer in a periodic fashion. Cyclic pattern of recruitments of
coactivators to the promoters of estrogen responsive genes, such as
the cathepsin D (CATD) and pS2 genes, are well documented, and
appear to reflect the association of different protein complexes of
coactivators and/or corepressors with transcription factors in a
sequential, combinatorial or parallel fashion [29,30]. Recruitment
of both SRC-1 and SRC-3 was found to be dependent on p300,
which suggests a central coactivator role for p300. Intriguingly,
SRC-1 and SRC-3 bound to the EPO enhancer with different
cyclic patterns from p300. We speculate that p300 is required for
the binding of SRC-1 and SRC-3 to the enhancer in the first
round of recruitment after DFO treatment, but is no longer
required for the subsequent rounds of recruitment, due to changes
in the contexts of the enhancer and promoter of the gene, such as
the histone modifications occurring at the promoter region and the
physical contact between the enhancer and promoter via DNA
looping. We previously showed that Brm and Brg-1 are recruited
to the enhancer of the EPO gene after hypoxia treatment and are
required for hypoxia induction of the gene. In the current study,
we showed that depletion of p300 did not significantly impair the
recruitment of Brm/Brg-1 to the enhancer, suggesting that p300
Figure 7. Role of CBP in hypoxia induced transcription of HIF target genes. A, whole cell extracts were prepared from Hep3B cells
transfected with siscx or siCBP RNA duplexes for 72 h and then subjected to Western blot analysis using an antibody directed to CBP. B, C, D and E,
total RNA was extracted from Hep3B cells transfected with siscx or siCBP RNA duplexes for 72 h and then subjected to reverse transcription and real-
time PCR using primers for the EPO, VEGF, PGK and LDHA genes. N: normoxia. H: hypoxia. * indicates statistically significant difference (p,0.05).
doi:10.1371/journal.pone.0010002.g007
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and Brm/Brg-1 belong to different protein complexes. To further
investigate the relationship between p300 and Brm/Brg-1, we
assessed hypoxia induced expression of EPO in cells knocked
down for p300 and Brm/Brg-1 simultaneously, and observed that
the effects of knocking down these coactivators was additive,
supporting our notion that p300 and Brm/Brg-1 belong to
different protein compelexes.
We then studied histone modifications at the promoter region,
focusing on lysine residues previously identified as substrates of
p300, SRC-1 or SRC-3 by other investigators using in vitro
acetylation assays. We found that lysine at position 23 of histone 3
(H3K23) was acetylated after hypoxic stimulation. We also
observed that hypoxia induced strong acetylation at lysines 5, 8,
12, and/or 16 of histone 4 and that this acetylation occurred in a
cyclic fashion upon treatment with DFO, suggesting that
deacetylases may be recruited to the promoter non-synchronously
with HATs during regulation of EPO expression. We further
investigated the role of p300 in the histone modifications and
observed that the hypoxia-stimulated acetylations at K23 of H3
and K5K8K12K16 of H4 at the promoter were eliminated in cells
depleted for p300, suggesting that they are bona fide substrates of
p300 or p300-bound HATs.
We also investigated the roles of p300 and p160 coactivators in
hypoxia induced transcription of the endogenous HIF-1a target
genes VEGF, PGK and LDHA, in addition to the HIF-2a target
gene, EPO. Surprisingly, while p300 was required for hypoxia
induction of EPO and VEGF, it appeared to be dispensable for
induction of PGK and LDHA. SRC-3 was required for hypoxia
induction of PGK and VEGF but not for that of LDHA, while
SRC-1 appeared not to be required for the hypoxia induced
transcription of any of the genes that we examined in this study,
suggesting that SRC-1 is either redundant or dispensable in
transactivation of these genes. These data suggests that coactiva-
tors may play different roles even in transcriptional regulation of
genes mediated by the same transcription factor. Although Brm
and Brg-1 are not required for transactivation of VEGF [26], they
appeared to be required for hypoxia induction of LDHA and
PGK, suggesting that the promoters of both of these latter genes
maintain compacted nucleosomal configurations which need to be
remodeled by the SWI/SNF protein complex. SRC-1 was
previously shown to enhance the transactivation potential of
HIF-1a [14,15], which might appear to be in contradiction to our
observations. This discrepancy could be explained by the fact that
the previous reports investigated the function of SRC-1 by
overexpressing it together with a reporter gene driven by the
EPO enhancer and a cDNA for HIF-1a, while we studied the
expression of endogenous HIF-responsive genes via siRNA-
mediated knock down. Overexpressed proteins can exhibit
artificial effects, and studies of transcriptional regulation using
reporter genes may lead to loss of target gene specificity.
CBP is a homolog of p300. The high degree of homology
between CBP and p300 suggests that these proteins could, at least
in part, be functionally redundant, and they are frequently found
to be interchangeable when transiently overexpressed in cells [36].
However, accumulating evidence indicates that CBP and p300
also have unique roles in vivo [31]. Both proteins have been shown
to bind the C-terminals of HIF-1a and HIF-2a and potentiate
their transcriptional activities [4,14,15,16,17]. Hence, it is of
interest to study whether/how they function differentially in
hypoxia induced transcription of endogenous HIF target genes.
Knocking down CBP by siRNA marginally, but significantly
decreased the hypoxia induced transcription of the EPO gene,
suggesting that both p300 and CBP are required for hypoxia
induction of EPO, and that neither can completely compensate for
the function of the other in transcriptional regulation of this gene.
Surprisingly, knocking down CBP resulted in enhancement of
expression of other HIF-1a regulated genes, including VEGF,
PGK and LDHA. These data suggest that CBP and p300 play
different roles in transactivation of the VEGF gene and they may
be redundant or dispensable in transactivation of the LDHA and
PGK genes.
It should be noted that in the adult organism the majority of
EPO protein is produced by the renal interstitial cells where an
element lying a considerable distance 59-upstream (between 29.5
and 214 kb) of the gene directs its expression [37,38]. Further
studies of EPO regulation in renal interstitial cells will be
important, given that these cells are of medical relevance in adults.
While HIF-1a was the first HIF-a subunit to be identified and has
been most extensively studied, recent examination of HIF-2a in the
context of both development and tumorigenesis demonstrates
significant differences in the biological function of these two proteins
[39]. Therefore, it will be of interest to investigate how HIF-1a and
HIF-2a exert these different physiological effects. One possible
mechanism underlying their different roles in physiological processes
is that they regulate different hypoxia inducible genes [39].
Taken together, our studies further illuminate the roles that
coactivators play in transcriptional regulation of EPO and other
HIF target genes and establish a central coactivator role of p300 in
hypoxia-induced transcription of the EPO gene.
Supporting Information
Figure S1 Effect of knocking down p300, SRC-1 and SRC-3
with additional siRNAs on hypoxic induction of EPO, VEGF,
LDHA and PGK. A, Hep3B cells were transfected with sip3009,
siSRC-19, siSRC-39 and the scrambled RNA duplex, used as
control. The sense sequences of sip3009, siSRC-19, siSRC-39 and
SCX, a scrambled RNA oligonucleotide, are r(GAAAUUAG-
GUUACACAACAUU), r(CAGCGGGAACUGUACAGU-
CAA)d(TT), r(AAGGUUGUCAAUAUAGAUACA)d(TT) and
r(UUCUCCGAACGUGUCACGU)d(TT). The cells were har-
vested and the whole cells extracts were prepared 72 h after
transfection. Western blot were done using the whole cells extracts
and the antibodies as indicated. B, C, D and E, Hep3B cells were
transfected with siRNAs for 72 h. During the last 24 h the cells
were treated with 1% O2. Total RNA were isolated and subjected
to reverse transcription and real-time PCR. Each of the real-time
PCRs was done three times and one representative result is
presented. This result represent an average from three real-time
PCR reactions with the same template. These genes mRNAs were
normalized to that of the constitutively expressed 36B4 gene
encoding a ribosomal subunit. * indicates statistically significant
difference from the cells transfected with the non-targeting
sequence (siscx) (p,0.01).
Found at: doi:10.1371/journal.pone.0010002.s001 (0.56 MB TIF)
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